Table 10--Artificial Seawater Nutrient Concentrations
------------------------------------------------------------------------
                                                              Final
                      Constituent                       concentration, g/
                                                                L
------------------------------------------------------------------------
* FeCl3 [middot] 6H2O.................................             0.050
KNO3..................................................             2.890
* Na5P3O10............................................             0.297
------------------------------------------------------------------------
* Added aseptically after the GP2 has been autoclaved to limit
  phosphorus and iron precipitation.

    5.3.3 Seawater for bioremediation agents that do not include
nutrients. If a bioremediation agent contains living microorganisms
but not nutrients (or limiting concentrations of nutrients), then
nutrients may be added by the manufacturer. However, the total
concentration of the nutrients added to the bioremediation agent
must not exceed the final concentrations listed in Table 11 of this
Appendix.

Table 11--Artificial Seawater Nutrient Concentrations for BioRemediation
                   Agents Having No Nutrients Included
------------------------------------------------------------------------
                Constituent                   Final concentration, g/L
------------------------------------------------------------------------
as Iron (Fe)..............................  0.010
as Nitrogen (N)...........................  0.400
as Phosphorus (P).........................  0.075
------------------------------------------------------------------------

If nutrients are supplied by the product manufacturer, the specific
composition and concentration used in the efficacy testing must be
submitted.
    5.3.4 Freshwater Preparation. The artificial freshwater, which
is a modification of Bushnell-Haas medium (Haines et al., 2005), is
prepared following the concentrations listed in Table 12 of this
Appendix and then autoclaved. The pH is adjusted to 7.4 before
autoclaving. Constituents removed from the original formulation are
KNO3, K2HPO4 and KH2PO4.

     Table 12--Constituent Concentrations for Artificial Freshwater
                             [Bushnell-Haas]
------------------------------------------------------------------------
                                                              Final
                      Constituent                         concentration
                                                             (mg/L)
------------------------------------------------------------------------
MgSO4 [middot] 7H2O...................................               200
CaCl2 [middot] 2H2O...................................                20
FeCl3 [middot] 6H2O...................................                50
MnSO4 x H2O...........................................            0.0302
H3BO3.................................................            0.0572
ZnSO4 x 7H2O..........................................            0.0428
(NH4)6Mo7O2...........................................            0.0347
------------------------------------------------------------------------

    5.3.5 Freshwater for the positive control. To prepare the
freshwater for the positive controls, prepare the nutrients
potassium phosphate monobasic (KH2PO4), potassium phosphate dibasic
(K2HPO4) and potassium nitrate (KNO3) as a concentrated solution.
Filter sterilize and add to autoclaved artificial freshwater to
obtain the final concentrations given in Table 13 of this Appendix.
Calibrate the pH meter at room temperature (approximately 20-23
[deg]C) using commercial buffers of pH 4.0, 7.0, and 10.0, as
appropriate, prior to use. Adjust the pH of the artificial
freshwater to 7.4 with 1 N HCl or 1 N NaOH, as appropriate.

              Table 13--Freshwater Nutrient Concentrations
------------------------------------------------------------------------
                                                              Final
                      Constituent                       concentration (g/
                                                             L) \1\
------------------------------------------------------------------------
KNO3..................................................              2.89
KH2PO4................................................              1.00
K2HPO4................................................              1.00
------------------------------------------------------------------------
\1\ Adjust pH to 7.4 prior to autoclaving.

    5.3.6 Freshwater for bioremediation agents that contain living
microorganisms but not nutrients or limiting concentrations of
nutrients. If a bioremediation agent does not include nutrients,
then nutrients may be added. However, the total concentration of the
nutrients added to the bioremediation agent must not exceed the
final concentrations provided in Table 14 of this Appendix.

       Table 14--Artificial Freshwater Nutrient Concentrations for
           Bioremediation Agents Having No Nutrients Included
------------------------------------------------------------------------
                Constituent                 Final concentration, g/L \1\
------------------------------------------------------------------------
as Iron (Fe)..............................  not added since iron is
                                             already in the freshwater
                                             solution.
as Nitrogen (N)...........................  0.400.
as Phosphorus (P).........................  0.400.
------------------------------------------------------------------------
\1\ Adjust to pH 7.4 prior to autoclaving.

If nutrients are supplied by the product vendor, the specific
composition and concentration used in the efficacy testing must be
submitted.
    5.3.7 Oil Preparation. The test oil, weathered ANS521 crude oil,
can be obtained from EPA at no charge (except for a minimal shipping
fee). See https://www.epa.gov/emergency-response/national-contingency-plan-subpart-j#howto for more information.
    5.3.8 Sodium azide sterilant. Prepare a stock solution of
NaN3 for addition to the negative killed control. The
final concentration in the killed controls will be 0.5 g/L.
    5.4 Experimental Setup and Procedure
    5.4.1 Autoclave clean borosilicate glass Erlenmeyer flasks (250
mL) for 20 minutes at 121 [deg]C at 15 psig.
    5.4.2 Label flasks with the appropriate code (negative control,
positive control, or product; day to be sampled (0 or 28); letter
indicating replicate number) to reflect the following treatment
design in Table 15 of this Appendix:

  Table 15--Bioremediation Efficacy Test--Summary of Experimental Setup
------------------------------------------------------------------------
                                               Number of
                                             replicates at
                Treatment                   sampling times     Analysis
                                          ------------------
                                            Day 0    Day 28
------------------------------------------------------------------------
Negative (killed) Control (oil + exposure        0        3        GC/MS
 water + product + EPA consortium + NaN3
 sterilant)..............................
* Positive control (oil + exposure water         6        6        GC/MS
 + nutrients + EPA consortium)...........
Test Type 1: Product containing living           6        6        GC/MS
 microorganisms (oil + exposure water +
 living product + supplemented nutrients
 (if necessary)).........................
Test Type 2: Product containing                  6        6        GC/MS
 proprietary nutrients but no live
 microorganisms (oil + exposure water +
 product + EPA consortium)...............
Test Type 3: Product (such as an enzyme)         6        6        GC/MS
 containing no live microorganisms and no
 nutrients (oil + exposure water +
 product)................................
------------------------------------------------------------------------
* The laboratory must report positive control test results conducted
  within the year of any test results for bioremediation products, for
  one or both types of water as applicable.

    5.4.3 Aseptically dispense 100 mL of pre-sterilized artificial
exposure water (seawater or freshwater) into each sterile flask. For
the positive control flasks, use exposure water containing
nutrients.
    5.4.4 Tare the labeled flasks containing exposure water and
other additions, as necessary, on the balance with a minimum
accuracy of 0.01 g. Add drop-wise 0.50 g oil (this results in a
final oil concentration of 5 g/L) using a sterile Pasteur pipette to
the center of the flask taking care to avoid splashing the oil onto
the sides of the flasks. Record the precise weight. ANS521 may be
previously warmed in a hot water bath at 60 [deg]C for 40-60 minutes
to facilitate its flow. Take precautions when handling and charging
the flasks to minimize the likelihood of contamination by exogenous
microbes, including using a new sterile pipette for each series of
flasks.
    5.4.5 Preparation of the EPA consortium for both the positive
control flasks and the flasks containing non-living bio-stimulation
products. Use the supplied vials containing approximately 5 mL of
the known EPA consortium frozen in glycerol. Thaw the supplied vials
at room temperature (do not allow cultures preserved in glycerol to
sit at room temperature past thawing), transfer the contents of the
thawed vials to a single sterile centrifuge tube, rinse tubes with
two volumes each of sterile exposure water, centrifuge at between
6,000- and 7,000-times gravity (6,000-7,000 x g) for 15 minutes
using a fixed rotor to fully pellet the cells. Carefully resuspend
the cell pellet in sterile exposure water using the appropriate
volume to achieve the desired seeding density, which will be
provided by EPA upon shipment of the consortium.
    5.4.6 Positive control flasks contain exposure water, oil,
nutrients, and the EPA consortium.
    5.4.7 Negative killed control flasks for all products shall
contain exposure water, oil, product, the EPA consortium for
products not containing a living culture, and the sodium azide
sterilant at a final concentration of 0.5 g/L. Add the sodium azide
sterilant prior to adding any product or EPA consortium. For the
negative killed control flasks and product flasks, prepare and add
the product to the flasks in a concentration specified by the
manufacturer or vendor.
    5.4.8 For non-living products that contain nutrient only, use
the EPA consortium as the inoculum.
    5.4.9 For other non-living products (e.g., enzymes), do not add
nutrients or the EPA consortium as the inoculum as they are not
needed.
    5.4.10 For products containing living microorganisms, prepare 6
flasks the same way as in Steps a-d, but without the EPA consortium.
A product that contains its own nutrients must not be amended with
nutrients, unless the product contains insufficient nutrients. Since
this is a closed flask test, nutrients could be limiting if they are
at the same concentration as used in the field. This could cause the
product to fail the test. Thus, the manufacturer has the option to
supplement its product with a higher concentration of nutrients than
that contained in the product. Any nutrient supplements to a product
must be reported and must not exceed the concentration limits in
Table 10 (for seawater) and 13 (for freshwater) of this Appendix, as
applicable.
    5.4.11 Cap all flasks either with sterile cotton stoppers or
loosely applied aluminum foil to allow gas exchange with the
atmosphere. Set aside the T = 0 flasks for immediate extraction and
analysis. Place the rest of the flasks onto the orbital shaker
table. Do not tip the flasks excessively to avoid stranding oil
above the mixing area of the flask. Set the orbital shaker to 200
rpm and shake the flasks for 28 days at 20-23 [deg]C in the dark.
    5.4.12 Submit all information on added microorganisms and
nutrients for testing in the data report.
    5.5 Sampling and Chemical Analysis.
    5.5.1 Summary. At each sampling event (Days 0 and 28), product
and control flasks are sacrificed for analysis of residual oil
concentrations (SOP 4 of this Appendix). Record all physical
observations for each flask (such as degree of emulsification,
whether the oil has congealed into tar balls, wall growth, color,
etc.) at each sampling. The analytical procedure is summarized in
Table 16 of this Appendix. Dichloromethane (DCM) is the solvent used
for the initial extraction. Solvent-exchange the extract into hexane
prior to injection into the gas chromatograph. The solvent exchange
is done to prevent asphaltenes from contaminating the column.

                       Table 16--Bioremediation Efficacy--Summary of Analytical Procedures
----------------------------------------------------------------------------------------------------------------
                                       Sampling/                    Sample container/  Preservation/    Holding
    Matrix         Measurement        measurement       Analysis       quantity of        storage        times
                                        method           method          sample          ([deg]C)      (months)
----------------------------------------------------------------------------------------------------------------
DCM...........  N/A..............  Solvent Exchange  N/A..........  Capped Vial with               4           6
                                    to Hexane.                       Teflon septa,
                                                                     30 mL.

Hexane........  Hydrocarbon        SOP 4...........  GC/MS........  Capped Vial with               4           6
                 Concentration.                                      Teflon septa,
                                                                     10 mL.
----------------------------------------------------------------------------------------------------------------

    5.5.2 Hydrocarbon Extraction. To measure extraction efficiency,
200 [micro]L of the 400 mg/L surrogate recovery standard (compounds
and concentrations described in SOP 1 in this Appendix) is added to
each flask. Add 50 mL DCM to each flask. Transfer the contents to a
250 mL separatory funnel and shake for 2 minutes; allow the phases
to separate for 2 minutes. If an emulsion remains after 2 minutes,
centrifuge the emulsion in Teflon[supreg] centrifuge tubes for at
least ten minutes in a low-speed centrifuge at 3,000 times gravity
(3,000 x g) to break the emulsion and recover the DCM phase. Pass
the DCM extract through a funnel plugged with glass wool and
containing approximately 20 g anhydrous, granular sodium sulfate
(Na2SO4) to remove water. Repeat the steps
above two more times with 25 mL DCM each (100 mL DCM used in total).
Add 10 mL DCM on to the sodium sulfate after the third extraction to
rinse off any oil residue. Collect the extract in 125 mL serum
vials, capped with Teflon lined septa and aluminum crimp seals, and
store at 4 [deg]C for up to 6 months.
    5.5.3 Solvent Exchange. Perform a solvent exchange (DCM to
hexane) prior to GC/MS analysis to prevent injection of asphaltenes
into the GC/MS column. Transfer the DCM extract to concentration
tubes. Place the tubes in a 29 [deg]C water bath under a stream of
dry nitrogen gas. Reduce the sample to 1 mL and transfer the extract
to a 10 mL volumetric flask. Rinse the concentration tube with
hexane and add it to the volumetric flask 2 times. Adjust the final
volume with hexane to 10 mL.
    5.5.4 Hydrocarbon Analysis. Quantify the concentrations of 25
alkanes, 32 aromatics and hopane (SOP 4, Table SOP 4.4 of this
Appendix) using an Agilent 6890 GC/5973 MS or equivalent equipped
with a 30-m x 0.25-mm ID x 0.25-[mu]m film thickness DB-5 or
equivalent fused silica column. To prepare the samples, transfer 1.0
mL of the hexane extract into a 2 mL autosampler vial with Teflon
lined cap. Add 20 [mu]L of internal standard solution to each vial
with a syringe or positive displacement pipettor. SOP 2 of this
Appendix outlines the procedure for preparing the internal standard
solution. Load vials onto the autosampler tray and analyze in
selected ion monitoring mode (SIM). Sum the individual alkane
concentrations for the total alkane concentration and the individual
aromatic concentrations for total aromatic concentrations in each
flask.
    5.6 Quality Assurance/Quality Control (QA/QC).
    5.6.1 Objectives. The critical variables to be analyzed for each
set of experimental conditions are the individual petroleum
hydrocarbons, i.e., the alkanes ranging in carbon number from nC-14
to nC-35, plus pristane and phytane, and the 2- to 4-ring polycyclic
aromatic hydrocarbons (PAHs) and their alkylated homologs as listed
in SOP 4 of this Appendix. The quality assurance objectives for
precision, accuracy, and detection limits are 20%, 75-
125% recovery, and 22.5 [micro]g/L on average for the 58 compounds,
respectively. For more details, refer to the SOPs of this Appendix.
    5.6.2 Precision Objectives. Precision is presented as relative
percent difference (RPD) for duplicate measurements and as relative
standard deviation (RSD, or coefficient of variance) for triplicate
measurements, applicable to replication of treatments as separate
samples.
    5.6.3 Accuracy Objectives. These are based on the check
standards and standard oil samples run concurrently with the sample
analyses for GC/MS analysis of critical compounds. Critical
compounds in the check standards and in the oil standards must fall
within 75-125% of expected values for the analysis to be valid. Six
surrogate compounds (SOP 1 of this Appendix) added to each sample
before extraction can also serve as a surrogate for determining
accuracy. The measured surrogate concentrations must fall within 75-
125% of expected values.
    5.6.4 Calibration Range. Conduct all measurements within the
linear calibration range of the instrument. The calibrated
concentration range for GC/MS analysis is 0.1 mg/L to 30 mg/L. If
the measured concentration of any critical compound is above the
calibration range, dilute the sample and re-analyze to quantify that
particular compound within the linear calibration range.
    5.6.5 Quality Control. Table 17 of this Appendix summarizes the
QC checks for each measurement. See the corresponding SOP in this
Appendix for detailed descriptions of QC checks, frequency,
acceptance criteria, and corrective actions.

                                             Table 17--QA/QC Checks
----------------------------------------------------------------------------------------------------------------
                                                                                Acceptance
 Sample matrix       Measurement         QA/QC check         Frequency           criteria      Corrective action
----------------------------------------------------------------------------------------------------------------
DCM............  GC/MS hydrocarbon   Blanks............  Once per           Peak area of       Flush with
                  analysis.                               calibrated run.    interfering        solvent, clean
                                                                             peaks <10% of      injection port,
                                                                             lowest standard    and/or bake
                                                                             peak area.         column.
DCM............  GC/MS hydrocarbon   DFTPP Check         Once per           Must pass all      If any criteria
                  analysis.           Standard.           calibrated run.    DFTPP criteria.    fail, retune and
                                                                                rerun DFTPP
                                                                                check standard.
DCM............  GC/MS hydrocarbon   Initial             Once per           Response Factor    If RSD for any
                  analysis.           Calibration         calibrated run.    RSD <=25% or R2    one compound
                                      Samples.                               >0.99.             >25%,
                                                                                recalibrate.
DCM............  GC/MS hydrocarbon   Calibration Check   Every 10-15        25%    If >5 compounds
                  analysis.           Standards.          samples.           of expected        are out of
                                                                             values.            range,
                                                                                recalibrate and
                                                                                rerun samples.
Hexane.........  GC/MS hydrocarbon   Surrogates........  Every Sample.....  30%    Re-inject.
                  analysis.                                                  of expected
                                                                             values.
Hexane.........  GC/MS hydrocarbon   Biomarker           Every Sample.....  25%    Re-inject.
                  analysis.           Concentration.                         of average
                                                                             values.
----------------------------------------------------------------------------------------------------------------

    5.7 Pass/Fail Criteria.
    5.7.1 Calculate the mean and standard deviation of the hopane-
normalized total aromatics (sum of all resolved aromatics) and
hopane-normalized total alkane concentrations (sum of all resolved
alkanes) from the 6 independent replicates at days 0 and 28. To
normalize, divide the sum of the alkane analytes and the sum of the
aromatic analytes in each replicate by the hopane concentration in
the corresponding replicate.
    5.7.2 From those data, calculate the 95% Upper Confidence Level
(UCL95) at days 0 and 28 using the following formula (Equation 11 of
this Appendix):

[GRAPHIC] [TIFF OMITTED] TR12JN23.089

where:

xt(0and28) = total hopane-normalized alkane or
total hopane-normalized aromatic mean of 6 replicates at days 0 and
28,
t95, 5 df = the 95% one-tailed t-value with 5 degrees of
freedom (2.015),
s = the standard deviation of the 6 replicates at day 0 and 28, and
n = no. of replicates = 6.

    5.7.3 Using Equation 12 of this Appendix, calculate the %
reduction of each oil fraction from day 0 to day 28, using the day 0
and 28 UCL95 hopane-normalized values for each fraction:
[GRAPHIC] [TIFF OMITTED] TR12JN23.090

where:

t28(UCL95) = UCL95 of the hopane-
normalized total alkane or total aromatic mean of 6 replicates on
day 28, and
t0(UCL95) = UCL95 of the hopane-normalized
total alkane or total aromatic mean of 6 replicates on day 0.

    5.7.4 A product is successful in saltwater or freshwater if the
% reduction of total alkanes (aliphatic fraction) from the GC/MS
analysis is greater than or equal to 85% and the % reduction of
total aromatics (aromatic fraction) is greater than or equal to 35%
at day 28 based on the UCL95 (Equation 12 of this
Appendix). The benchmark reduction ranges in aliphatic and aromatic
fractions for the positive control are the same as for the products
specified above. The average concentration of the biomarker hopane
at day 28 must not differ from the average concentration at day 0 by
more than 12% in the positive control. If the conditions for the
positive control are not met, the entire procedure must be repeated.
    5.8 Data Verification and Reporting. GC/MS data files are
generated by MS ChemStation software (the Agilent standard software
for GC/MS) or equivalent for each injection. Data files contain
summed ion chromatograms and selected ion chromatograms. Calibration
curves are generated within MS ChemStation software, and all data
files are calculated against the calibration curve by MS
ChemStation. Data verification would be done by crosschecking
between analysts for 10% of the raw data and its reduction process.
    5.9 Laboratory Report. The summary of findings from a product
test must include the data listings for each analyte that was
analyzed (i.e., all individual alkanes and aromatics in the list of
required analytes), along with QA/QC checks (see Table 17) and
instrument detection/reporting limits for each analyte. Express all
concentrations as mg analyte/L exposure water.
    5.10 Standard Operating Procedures (SOPs) 1-4
    5.10.1 SOP 1. Preparation of Surrogate Recovery Standards
    <IP_ADDRESS> Preparation:
    <IP_ADDRESS>.1 Solvents: Dichloromethane (DCM), Optima grade or
equivalent.
    <IP_ADDRESS>.2 Reagents:

D36-Heptadecane (C17)
D50-Tetracosane (C24)
D66-Dotriacontane (C32)
D10-1-Methylnaphthalene
D10-Phenanthrene
D10-Pyrene
5-beta-cholestane (coprostane)

Note: Deuterated reagents are available from Cambridge Isotope
Laboratories, Andover, MA.
    <IP_ADDRESS>.3 Equipment:

Micro-spatula
Small beakers
Glass funnel
Analytical balance (0.0001g)
Vials with Teflon-lined caps
Teflon wash bottle with Optima grade DCM
Volumetric flask (250 mL), class A
Pasteur pipettes

    <IP_ADDRESS> Procedure:
    <IP_ADDRESS>.1 Using a calibrated analytical balance, weigh 100 mg
(0.100 g) of each reagent into separate 10-25 mL beakers.
    <IP_ADDRESS>.2 Dissolve the reagents in their beakers by adding 10
mL DCM. Use a Pasteur pipette to transfer the solutions to a single
250 mL volumetric flask.
    <IP_ADDRESS>.3 Wash the beakers 3 or 4 times with DCM. Use a Pasteur
pipette to transfer each of the washings to the 250 mL volumetric
flask.
    <IP_ADDRESS>.4 Dilute the solution to the 250 mL volume mark on the
volumetric flask with DCM.
    <IP_ADDRESS>.5 Use a glass stopper to seal the flask and homogenize
the solution by inverting the flask 5 or more times. The final
concentration of this solution is 400 mg/L for each of the reagents.
    <IP_ADDRESS>.6 Transfer the solution into 40 mL storage vials and
cap with Teflon-lined caps and label each with the date of
preparation, operator, sample names, and concentrations.
    <IP_ADDRESS>.7 Weigh each vial and record its weight on the label.
This weight is used to monitor possible evaporation during storage.
    <IP_ADDRESS>.8 Store these vials at 0 [deg]C or lower.
    <IP_ADDRESS>.9 Before using, allow the solution to come to room
temperature, and then shake it well.
    <IP_ADDRESS>.10 Weigh the vial before using it and compare the
weight with the last weight recorded on the vial.
    <IP_ADDRESS>.11 If the weights are consistent, the integrity of the
solution can be assumed. If not, investigate and resolve the cause.
Prepare a new solution if the integrity has been compromised.
    <IP_ADDRESS> Quality Control: Inject 20 [mu]L of the surrogate stock
solution into 1 mL DCM. Add 20 [mu]L of the internal standard
solution (SOP 2 of this Appendix). Analyze this solution by GC/MS
using a calibrated method (SOPs 3 and 4 of this Appendix). The
expected concentration of each of the corresponding surrogate
compounds is 8  2 mg/L. If the measured value does not
fall within this range, prepare and measure another independent
surrogate solution. If the measured concentration of the second
surrogate solution is within the allowable tolerance range, the
calibration and instrument conditions are acceptable; properly
discard the first surrogate solution. If the concentration of the
second surrogate solution is also out of range, then clean and
recalibrate the instrument until the problem is resolved.
    5.10.2 SOP 2. Preparation of Internal Standard Solution
    <IP_ADDRESS> Preparation:
    <IP_ADDRESS>.1 Solvents: Dichloromethane (DCM), Optima grade or
equivalent
    <IP_ADDRESS>.2 Reagents:

D34 n-Hexadecane (C16)
D42 n-Eicosane (C20)
D62 n-Triacontane (C30)
D8-Naphthalene
D10-Anthracene
D12-Chrysene
5-alpha-Androstane

    Note: Deuterated reagents are available from Cambridge Isotope
Laboratories, Andover, MA.
    <IP_ADDRESS>.3 Equipment:

 Micro-spatula
Small beakers
Glass funnel
Analytical balance (0.0001g), calibrated and checked for accuracy
Amber vials with Teflon-lined caps, labeled
Teflon wash bottle with DCM
Volumetric flask (200 mL), class A
Pasteur pipettes

    <IP_ADDRESS> Procedure:
    <IP_ADDRESS>.1 Using a calibrated analytical balance, weigh 100 mg
(0.100 g) of each of the reagents into separate small beakers.
    <IP_ADDRESS>.2 Dissolve the reagents in their beakers by adding 10
mL DCM; using a Pasteur pipette, transfer the solutions to a single
200 mL volumetric flask.

    <IP_ADDRESS>.3 Wash the beakers 3 or 4 times with DCM; use a Pasteur
pipette to transfer each of the washings to the 200 mL volume mark
on the volumetric flask.
    <IP_ADDRESS>.4 Dilute the solution with DCM to the 200 mL volume.
    <IP_ADDRESS>.5 Seal the flask with a glass stopper and homogenize
the solution by inverting the flask a minimum of 5 times. The final
concentration of this solution is 500 mg/L of each reagent.
    <IP_ADDRESS>.6 Transfer the solution into 40 mL storage vials and
cap with Teflon-lined caps. Label each vial with the date of
preparation, operator, sample names, and concentrations.
    <IP_ADDRESS>.7 Weigh each vial, and record its weight on the label.
This weight is used to monitor possible evaporation during storage.
    <IP_ADDRESS>.8 Store this solution at 0 [deg]C or lower.
    <IP_ADDRESS>.9 Before using, allow the solution to come to room
temperature, and then shake it well.
    <IP_ADDRESS>.10 Weigh the vial before using it, and compare the
weight with the last weight recorded on the vial.
    <IP_ADDRESS>.11 If the weights are consistent, the integrity of the
solution can be assumed. If not, investigate and resolve the cause.
Prepare a new solution if the integrity has been compromised.
    <IP_ADDRESS> Quality Control: Inject 20 [mu]L of the internal
standard solution into 1 mL DCM. Analyze this solution by GC/MS. The
only peaks corresponding to the internal standards must appear. If
other peaks appear, particularly close to the internal standard
peaks, discard the internal standard solution and prepare a new
solution.
    5.10.3 SOP 3. Preparation of Working Standards, Check Standards,
and Oil Standards for GC/MS Consistency.
    <IP_ADDRESS> Preparation:
    <IP_ADDRESS>.1 Solvent: Dichloromethane (DCM), Optima grade or
equivalent
    <IP_ADDRESS>.2 Stock solutions:
    <IP_ADDRESS>.2.1 Oil analysis standard: 44 compounds, 100 mg/L in
hexane/DCM (9:1), four, 1-mL vials required. Available from Absolute
Standards, Inc., Hamden, CT, Part #90311.
    <IP_ADDRESS>.2.2 Nine compound PAH standard: 1,000 mg/L in DCM, one
vial. Available from Absolute Standards, Inc., Hamden, CT, Part
#90822.
    <IP_ADDRESS>.2.3 1,2-Benzodiphenylene sulfide, (synonym for
naphthobenzothiophene). Prepare a 2 mg/mL stock solution. Available
from Sigma-Aldrich Co., Part # 255122, purity 99%.
    <IP_ADDRESS>.2.4 Hopane solution (17 [alpha] (H), 21[beta] (H), 0.1
mg/mL in isooctane. Available from Sigma-Aldrich Co. Part #90656.
    <IP_ADDRESS>.2.5 Surrogate solution: 400 mg/L of each reagent in DCM
(see SOP 1 of this Appendix).
    <IP_ADDRESS>.2.6 Internal standard solution, 500 mg/L in DCM (see
SOP 2 of this Appendix).
    <IP_ADDRESS>.3 Alaska North Slope Crude Oil 521 (ANS521).
    <IP_ADDRESS>.4 Equipment:
    <IP_ADDRESS>.4.1 Glass storage vials with Teflon-lined caps (2 mL
and 40 mL capacity);
    <IP_ADDRESS>.4.2 Volumetric flasks, Class A, 5 mL, 10 mL, and 100 mL
    <IP_ADDRESS>.4.3 Glass syringes capable of dispensing 25-500
[micro]L with an accuracy and precision of  1%, or
equivalent
    <IP_ADDRESS>.4.4 Wheaton repetitive dispenser, Model 411 STEP-PETTE
or equivalent
    <IP_ADDRESS>.4.5 Teflon wash bottle filled with Optima grade DCM or
equivalent grade DCM
    <IP_ADDRESS>.4.6 Pasteur pipettes
    The volumes of stock solutions required to make the working
standards are listed in Table SOP 3.1 of this Appendix.

                                     Table SOP 3.1--Amount of Stock Solutions Required To Make the Working Standards
--------------------------------------------------------------------------------------------------------------------------------------------------------
            Stock standards                     A                B              C            D            E                                       F
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            1,2-Benzo-
                                           Oil analysis    Aromatics mix   diphenylene   Surrogate      Hopane
 Working standards concentration, mg/L       mix (44       (9 compounds,     sulfide      solution     solution    Volumetric flask volume    ISTD (500
                                          compounds, 100    1,000 mg/L)    (NBT) (2 mg/  (100 mg/L)   (100 mg/L)              mL             mg/L) [mu]L
                                           mg/L) [mu]L         [mu]L        mL) [mu]L      [mu]L        [mu]L
--------------------------------------------------------------------------------------------------------------------------------------------------------
STD 30 (no hopane).....................            1,500              150           75          375            0  5........................          100
STD 20 (5 mg/L hopane).................            1,000              100           50          250          250  5........................          100
STD 10 (2.5 mg/L hopane)...............              500               50           25          125          125  5........................          100
STD 5 * (1 mg/L hopane)................              500               50           25          125          100  10.......................          200
STD 5-Utility (1 mg/L hopane)..........              500               50           25          125          100  10 (used for preparation             0
                                                                                of STD 2.5 & STD 1).
                                        ----------------------------------------------------------------------------------------------------
STD 2.5 (0.5 mg/L hopane)..............                            Use 5 mL of STD 5-Utility and dilute to 10 mL.                                    200
STD 1 (0.2 mg/L hopane)................                            Use 2 mL of STD 5-Utility and dilute to 10 mL.                                    200
STD 0.1 (0.2 mg/L hopane)..............                           Use 0.2 mL of STD 5-Utility and dilute to 10 mL.                                   200
--------------------------------------------------------------------------------------------------------------------------------------------------------
* Make extra STD 5 for use as check standard.

    <IP_ADDRESS> Procedure for Working Standards and Check Standards:
    <IP_ADDRESS>.1 Label three 5 mL volumetric flasks as STD30, STD20,
STD10, and two 10 mL volumetric flasks as STD5, and STD5-utility.
    <IP_ADDRESS>.2 Add 1-2 mL of DCM to each volumetric flask.
    <IP_ADDRESS>.3 Using glass syringes, add the appropriate volume of
stock solution A (as listed in Table SOP 3.1 of this Appendix) to
the flasks labeled STD30, STD20, STD10, STD5, and STD5-utility.
    <IP_ADDRESS>.4 Wash the walls of the inner neck of the flasks with
several drops of DCM to rinse off the residue of the stock solution
into the flasks.
    <IP_ADDRESS>.5 Repeat Step 3 and Step 4 to dispense stock solutions
B-E (do not add stock solution F, internal standard solution, at
this step).
    <IP_ADDRESS>.6 Dilute to volume with DCM for all the above flasks,
seal with glass stoppers, and invert several times to homogenize the
solutions.
    <IP_ADDRESS>.7 Label three additional 10 mL volumetric flasks as
STD2.5, STD1, and STD0.1. Wet with 1-2 mL DCM.
    <IP_ADDRESS>.8 Dispense 5 mL of STD5-utility solution into flask
STD2.5, 2 mL of STD5-utility solution into flask STD1, and 0.2 mL of
STD5-utility solution into flask STD0.1.
    <IP_ADDRESS>.9 Dilute to volume with DCM, seal with glass stoppers,
and invert several times to homogenize the solutions.
    <IP_ADDRESS>.10 Using a 100 [mu]L glass syringe, dispense 100 [mu]L
of internal standard solution into flasks STD30, STD20, and STD10.
Dispense 200 [mu]L into flasks STD5, STD2.5, STD1, and STD0.1 to
give a final concentration of 10 mg/L internal standard.
    <IP_ADDRESS>.11 Seal with glass stoppers, and invert the flasks
several times to homogenize the solutions.
    <IP_ADDRESS>.12 Transfer the solutions into 2 mL storage vials, and
cap with Teflon-lined caps.
    <IP_ADDRESS>.13 Label each vial with date of preparation, analyst,
sample names, and concentrations.
    <IP_ADDRESS>.14 Weigh each storage vial and record its weight on the
label. This weight is used to monitor possible evaporation during
storage.
    <IP_ADDRESS>.15 Store this solution at 0 [deg]C or below.
    <IP_ADDRESS>.16 Before using, allow the solution to come to room
temperature, and shake it well.
    <IP_ADDRESS>.17 Weigh the vial before opening, and compare the
weight with the last weight recorded on the vial. If the weights are
consistent, the integrity of the solution can be assumed. If not,
investigate and resolve the cause. Do not use the solution if the
integrity has been compromised.
    <IP_ADDRESS> Procedure for Oil Standard. In a 100 mL volumetric
flask, weigh 0.500 g of the standard ANS521 crude oil, add 2 mL of
surrogate solution (see SOP 1 of this

Appendix), and bring to volume with DCM. Add 2 mL of internal
standard solution (see SOP 2 of this Appendix). Follow steps
<IP_ADDRESS>.11 through <IP_ADDRESS>.17 of this SOP, substituting 40 mL
storage vials for the 2 mL vials.
    <IP_ADDRESS> Quality Control/Quality Assurance:
    <IP_ADDRESS>.1 Run the seven standard solutions using the GC/MS
method (SOP 4) on a tuned GC/MS. Use the EnviroQuant software or
equivalent to calculate the average Relative Response Factor (RRF)
and the relative standard deviation (RSD) of the RRFs for each
analyte over the six concentrations. The RRF is defined as:
[GRAPHIC] [TIFF OMITTED] TR12JN23.091

    <IP_ADDRESS>.2 The RSD of the RRFs for all analytes must be 25% or
less. Alternatively, the coefficients of determination (R2) for the
calibration curve for each target compounds and surrogate should be
over 0.99.
    5.10.4 SOP 4. GC/MS Method for the Analysis of Crude Oil
Samples.
    <IP_ADDRESS> Instrument Specifications:
    <IP_ADDRESS>.1 Use an Agilent 6890 GC coupled with an Agilent 5973
mass selective detector (MSD) and an Agilent 6890 series auto
sampler or equivalent, equipped with a DB-5 capillary column (30 m,
0.25 mm I.D., and 0.25 [mu]m film thickness) or equivalent, and a
split/splitless injection port operating in the splitless mode. Data
acquisition occurs in the SIM (selected ion monitoring) mode for
quantitative analysis. In SIM mode, the dwell time of each ion is
set to be 10 milliseconds and the ions are split up into groups by
retention time. One way to divide the ions is by retention time
grouping as shown in Table SOP 4.1 of this Appendix. The number of
ions in each ion group must be constant, yielding the same scan rate
for each group.

        Table SOP 4.1--Ions Associated With Retention Time Groups
------------------------------------------------------------------------
            Group                                 Ions
------------------------------------------------------------------------
1............................  57, 66, 128, 136, 142, 152, 156, 166,
                                170, 184.
2............................  57, 66, 166, 170, 178, 180, 184, 188,
                                192, 194, 198, 208.
3............................  57, 66, 178, 184, 188, 192, 194, 198,
                                202, 206, 208, 212, 220, 226.
4............................  57, 66, 192, 198, 202, 206, 208, 212,
                                216, 220, 226, 230, 234, 245.
5............................  57, 66, 191, 217, 228, 240, 242, 248,
                                256, 262, 264, 270, 276, 284.
------------------------------------------------------------------------

    <IP_ADDRESS>.2 Table SOP 4.2 of this Appendix summarizes the
instrumental conditions for crude oil analysis. Use only ultra-high
purity helium (99.999% pure) as the carrier gas. In series, connect
a moisture trap, an oxygen trap, and an organic trap to the carrier
gas line before it enters the column.

      Table SOP 4.2--Instrumental Conditions for Crude Oil Analysis
------------------------------------------------------------------------

------------------------------------------------------------------------
Instrument........................  Agilent 6890 Series II Gas
                                     Chromatograph (GC) with an Agilent
                                     5973MSD and an Agilent 6890 auto
                                     sampler, or equivalent.
Column............................  DB-5 capillary column (30 m, 0.25 mm
                                     I.D., and 0.25-mm film thickness)
                                     or equivalent.
Carrier Gas.......................  Helium, ultra-high purity grade
                                     (99.999%).
Inlet Temperature.................  300 [deg]C.
Transfer Line (detector)            310 [deg]C.
 Temperature.
Oven Temperature Program..........  50 [deg]C for 4 minutes, then 7
                                     [deg]C/min to 310 [deg]C, hold for
                                     18 minutes.
Flow Rate.........................  Constant flow at 1mL/min. Linear
                                     velocity: 36.2 cm/sec.
Injection Volume..................  1 [micro]L.
Split/Splitless Mode..............  Splitless.
Total Run Time....................  59.18 minutes.
------------------------------------------------------------------------

    <IP_ADDRESS> Procedure for preparing the instrument:
    <IP_ADDRESS>.1 Lower the injection port temperature and the oven
temperature to 50 [deg]C or less to avoid oxidation of the column.
    <IP_ADDRESS>.2 Replace the liner with a clean, silanized liner. Do
not touch the liner with bare fingers. A small piece of muffled
glass wool may be inserted to protect the column.
    <IP_ADDRESS>.3 Return the injection port and oven to the appropriate
temperatures.
    <IP_ADDRESS>.4 Wait five minutes after the temperature equilibrates
before using the instrument.
    <IP_ADDRESS> Procedure for tuning the MSD:
    <IP_ADDRESS>.1 Perform an air/water check. The value reported for
the relative abundance of water (m/z 18), nitrogen (m/z 28), oxygen
(m/z 32), or carbon dioxide (m/z 44) shall be less than 5% of the
base peak for the system to be considered leak free and are expected
to be closed to 1% for a stable system.
    <IP_ADDRESS>.2 Tune the MSD using the Standard Autotune program and
the decafluorotriphenylphosphine (DFTPP) Tune program to reduce
instrument variability. The Autotune report file is referenced by
the instrument when performing an air/water check and thus must be
run at least once per month. Run standards and samples using DFTPP
Tune parameters, and retune the instrument using DFTPP Tune at least
once per week. The tune programs use three fragment ions of
perfluorotributylamine (PFTBA) as a standard for tuning: m/z 69,
219, and 502. Tune reports must meet the following criteria:
    <IP_ADDRESS>.2.1 Symmetrical peaks;
    <IP_ADDRESS>.2.2 Mass assignments within 0.2 amu's from
69, 219, and 502;
    <IP_ADDRESS>.2.3 Peak widths within 0.5  0.1 amu's;
    <IP_ADDRESS>.2.4 Relative abundance is 100% for ion 69, at least 35%
for ion 219, and at least 1% for ion 502;
    <IP_ADDRESS>.2.5 Relative abundances for isotope masses 70, 220, and
503  0.2 amu's are 0.5-1.5%, 2-8%, and 5-15%,
respectively; and
    <IP_ADDRESS>.2.6 Air and water peaks at m/z = 18, 28, 32, and 44
amu's must be very small and consistent with historical values.
    <IP_ADDRESS> Maintaining a log book. Maintain an instrument log
book, and make entries for each use. Include the following
information in the logbook: operator name, helium cylinder tank
pressure and outlet pressure, vacuum gauge reading, any maintenance
performed on the instrument (such as changing the injection port
liner, gold seal, guard column, source cleaning), sequence

name, data path, samples in order of injection, method information,
GC column number, and the Standard Auto Tune report and DFTPP Tune
report.
    <IP_ADDRESS> Running a Solvent Blank: Following a liner change or at
the start of a new run, run an injection of a pure solvent to
confirm that the system is free of excessive or interfering
contamination. Analyze the solvent in SCAN mode using the same
temperature program used for sample analysis. If contamination is
present, analyze additional samples of fresh solvent until the
interfering contamination is removed.
    <IP_ADDRESS> Checking the DFTPP Tune: Prior to running the first
calibration standard, verify the instrument tune conditions by
running a 10 ng/[mu]L DFTPP check standard to check the mass
measuring accuracy of the MS, the resolution sensitivity, the
baseline threshold, and the ion abundance ranges. Run the standard
using the DFTPP method provided with the instrument. Each of the
criteria identified in Table SOP 4.2 of this Appendix must be met
before using the instrument for analysis:

                                 Table SOP 4.3--Ion Abundance Criteria for DFTPP
----------------------------------------------------------------------------------------------------------------
                                            Relative to       Relative abundance
                Mass, M/z                      mass                criteria              Purpose of checkpoint
----------------------------------------------------------------------------------------------------------------
51......................................             442  10-80% of the base peak...  Low mass sensitivity.
68......................................              69  <2% of mass 69............  Low mass resolution.
70......................................              69  <2% of mass 69............  Low mass resolution.
127.....................................             442  10-80% of the base peak...  Low-mid mass sensitivity.
197.....................................             198  <2% of mass 198...........  Mid mass resolution.
198.....................................             442  Base peak or >50% of 442..  Mid mass resolution and
                                                                                sensitivity.
199.....................................             198  5-9% of mass 198..........  Mid mass resolution and
                                                                                isotope ratio.
275.....................................             442  10-60% of the base peak...  Mid-high mass sensitivity.
365.....................................             442  >1% of the base peak......  Baseline threshold.
441.....................................             443  Present and < mass 443....  High mass resolution.
442.....................................             442  Base peak or >50% of 198..  High mass resolution and
                                                                                sensitivity.
443.....................................             442  15-24% of mass 442........  High mass resolution and
                                                                                isotopic ratio.
----------------------------------------------------------------------------------------------------------------

    <IP_ADDRESS> Calibrating with a Multiple-Point Calibration Curve. A
5- or 6-point calibration curve is obtained by running 5 or 6
working standards (see SOP 3) on the tuned GC/MS instrument.
Calculate the relative response factor (RRF) for each compound
relative to its corresponding deuterated internal standard as
indicated in Table SOP 4.3 of this Appendix. The relative standard
deviation (RSD) of the RRFs for each compound must be less than 25%.
Run an independently prepared check standard immediately after the
calibration standards to validate the accuracy of the calibration
curve.
    <IP_ADDRESS> Running Samples. Once the calibration curve has been
validated, samples can be analyzed. Dispense 1,000 [mu]L of sample
extract into labeled auto-sampler vials. Add 20 [mu]L of the
internal standard solution (see SOP 2 of this Appendix) to the
extract using a syringe or a positive displacement pipettor. Run a
check standard every 10 samples to ensure the consistency of the
instrument. The RRF for each compound in the check standard must be
within 25% of the average RRF obtained in the initial calibration.
    <IP_ADDRESS> Quantification: Once a calibration table has been
generated, quantify each data file using the ``Calculate and
Generate'' function in the MS ChemStation software, or equivalent
software. Review individual peak integration manually to ensure
proper baseline integration. The quantification of a compound is
based on the peak area of the primary ion (Q Ion) indicated in Table
SOP 4.4 of this Appendix.

                                       Table SOP 4.4--Target Compound List
----------------------------------------------------------------------------------------------------------------
                                           Quantitation     Reference compound for       Internal standard for
              Compound name                     ion             response factor              quantitation
----------------------------------------------------------------------------------------------------------------
N D34 C16...............................              66  N D34 C16.................  D34 n C16 Q Ion 66.
n-C14...................................              57  n C14.....................
n-C15...................................              57  n C15.....................
n-C16...................................              57  n C16.....................
N D34 C17...............................              66  N D34 C17.................
n-C17...................................              57  n C17.....................
Pristane................................              57  Pristane..................
n-C18...................................              57  n C18.....................
Phytane.................................              57  Phytane...................
n C19...................................              57  n C19.....................
N D42 C20...............................              66  N D42 C20.................  D42 n C20 Q Ion 66.
n C20...................................              57  n C20.....................
n C21...................................              57  n C21.....................
n C22...................................              57  n C22.....................
n C23...................................              57  n C23.....................
N D50 C 24..............................              66  N D50 C 24................
n C24...................................              57  n C24.....................
n C25...................................              57  n C25.....................
n C26...................................              57  n C26.....................
n C27...................................              57  n C27.....................
n C28...................................              57  n C28.....................
n C29...................................              57  n C29.....................
N D62 C30...............................              66  N D62 C30.................  D62 n C30Q Ion 66.
n C30...................................              57  n C30.....................
n C31...................................              57  n C31.....................
N D66 C32...............................              57  N D66 C32.................
n C32...................................              57  n C32.....................
n C33...................................              57  n C33.....................
n C34...................................              57  n C34.....................

n C35...................................              57  n C35.....................
D8 Naphthalene..........................             136  D8 Naphthalene............  D8 Naphthalene Q Ion 136.
Naphthalene.............................             128  Naphthalene...............
D10 1-Methylnaphthalene.................             152  D10 1-Methylnaphthalene...
C1 Naphthalene *........................             142  C1 Naphthalene............
C2 Naphthalene *........................             156  C2 Naphthalene............
C3 Naphthalene *........................             170  C3 Naphthalene............
C4 Naphthalene *........................             184  C3 Naphthalene............
D10 Anthracene..........................             188  D10 Anthracene............  D10 Anthracene Q Ion 188.
D10 Phenanthrene........................             188  D10 Phenanthrene..........
Phenanthrene............................             178  Phenanthrene..............
C1 Phenanthrene *.......................             192  C1 Phenanthrene...........
C2 Phenanthrene *.......................             206  C2 Phenanthrene...........
C3 Phenanthrene *.......................             220  C2 Phenanthrene...........
C4 Phenanthrene *.......................             234  C2 Phenanthrene...........
Fluorene................................             166  Fluorene..................
C1 Fluorene *...........................             180  Fluorene..................
C2 Fluorene *...........................             194  Fluorene..................
C3 Fluorene *...........................             208  Fluorene..................
Dibenzothiophene........................             184  Dibenzothiophene..........
C1 Dibenzothiophene *...................             198  Dibenzothiophene..........
C2 Dibenzothiophene *...................             212  Dibenzothiophene..........
C3 Dibenzothiophene *...................             226  Dibenzothiophene..........
Naphthobenzothiophene (NBT).............             234  Naphthobenzothiophene.....
C1 NBT *................................             248  Naphthobenzothiophene.....
C2 NBT *................................             262  Naphthobenzothiophene.....
C3 NBT *................................             276  Naphthobenzothiophene.....
Fluoranthene............................             202  Fluoranthene..............
D10 Pyrene..............................             212  D10 Pyrene................
Pyrene..................................             202  Pyrene....................
C1 Pyrene *.............................             216  Pyrene....................
C2 Pyrene *.............................             230  Pyrene....................
D12 Chrysene............................             240  D12 Chrysene..............  D12 Chrysene Q Ion 240.
Benzo(a)anthracene/Chrysene *...........             228  Chrysene..................
C1 Chrysene *...........................             242  Chrysene..................
C2 Chrysene *...........................             256  Chrysene..................
C3 Chrysene *...........................             270  Chrysene..................
C4 Chrysene *...........................             284  Chrysene..................
5[alpha]-androstane.....................             245  5[alpha]-androstane.......  5[alpha]-androstane Q Ion
                                                                                245.
Coprostane..............................             219  Coprostane................
Hopane..................................             191  Hopane....................
----------------------------------------------------------------------------------------------------------------
* Summed compounds; draw an integration line underneath all peaks with selected ion.

    <IP_ADDRESS> Equation 14 of this Appendix is used to calculate the
concentration of analytes in units of [mu]g/g oil added:
[GRAPHIC] [TIFF OMITTED] TR12JN23.092

where:

Aanalyte = the peak area of the analyte,
Cistd = the concentration of the internal standard,
Aistd = the area of the internal standard,
RRF = the relative response factor, and
100 is the conversion factor to convert mg/L DCM to [mu]g/g oil
added.

    <IP_ADDRESS> If some analytes are not commercially available, the
RRFs of other compounds (usually the parent compound) are used to
quantify those analytes. For example, the RRF of C3-naphthalene may
be used to calculate the concentrations of C3- and C4-naphthalenes.
See Table SOP 4.4 of this Appendix for details. The quantification
of these alkylated PAHs is relative because it is assumed that the
molecular ions of the alkylated PAHs have the same RRFs as the
parent compound ions. Nevertheless, these relative concentrations
are useful for monitoring the fate of these compounds during the
course of any analysis, as long as their concentrations are measured
in a consistent way throughout the analysis.
    <IP_ADDRESS> Concentration calculations for all target compounds
are performed using EnviroQuant software or equivalent. Data for
each sample can be printed directly using a customized report
template. Data can also be automatically entered into a spreadsheet
within the EnviroQuant software.
    5.10.5 Quality Assurance/Quality Control. The following criteria
must be met before any samples are analyzed:
    <IP_ADDRESS> Air/water check to verify the system is leak free.
    <IP_ADDRESS> AutoTune and DFTPP Tune pass all criteria.
    <IP_ADDRESS> DFTPP check standard passes all criteria.
    <IP_ADDRESS> Solvent blank scan indicates the GC/MS system is free
of interfering contamination.
    <IP_ADDRESS> Prepare and monitor a control chart of a standard oil
analysis.

Concentrations of the analytes in the control chart must be no more
than 25% different from their historical averages.
    <IP_ADDRESS> Relative response factors for analytes in the check
standards inserted between every 10 samples must be no more than 25
percent different from the average RRF of those same analytes in the
calibration curve. Peak shapes must be symmetrical.
    5.11 References for Section 5

(1) Haines, J.R., E.J. Kleiner, K.A. McClellan, K.M. Koran, E.L.
Holder, D.W. King, and A.D. Venosa. 2005. ``Laboratory evaluation of
oil spill bioremediation products in salt and freshwater systems.''
J. Ind. Microbiol. Biotech 32: 171-185.

Appendix E to Part 300 [Removed]

0
16. Remove Appendix E to Part 300.

[FR Doc. 2023-11904 Filed 6-7-23; 11:15 am]
BILLING CODE 6560-50-P


[Federal Register Volume 88, Number 38 (Monday, February 27, 2023)]
[Rules and Regulations]
[Pages 12170-12175]
[FR Doc No: 2023-03929]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

15 CFR Part 744

[Docket No.<PHONE_NUMBER>]
RIN 0694-AJ13

Additions of Entities to the Entity List

AGENCY: Bureau of Industry and Security, Department of Commerce.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Department of Commerce is amending the Export
Administration Regulations (EAR) by adding 10 entities under 13 entries
to the Entity List. These entities have been determined by the U.S.
Government to be acting contrary to the national security or foreign
policy interests of the United States. These entities are listed on the
Entity List under the destinations of Canada (2), China (5), France
(1), Luxembourg (1), Netherlands (1), and Russia (3).

DATES: This rule is effective February 24, 2023.

FOR FURTHER INFORMATION CONTACT: Chair, End-User Review Committee,
Office of the Assistant Secretary for Export Administration, Bureau of
Industry and Security, Department of Commerce, Phone:<PHONE_NUMBER>,
Email: [email protected].

SUPPLEMENTARY INFORMATION:

Background

    The Entity List (supplement no. 4 to part 744 of the EAR (15 CFR
parts 730-774)) identifies entities for which there is reasonable cause
to believe, based on specific and articulable facts, that the entities
have been involved, are involved, or pose a significant risk of being
or becoming involved in activities contrary to the national security or
foreign policy interests of the United States, pursuant to Sec.
744.11(b). The EAR impose additional license requirements on, and limit
the availability of, most license exceptions for exports, reexports,
and transfers (in-country) when a listed entity is a party to the
transaction. The license review policy for each listed entity is
identified in the ``License Review Policy'' column on the Entity List,
and the impact on the availability of license exceptions is described
in the relevant Federal Register document that added the entity to the
Entity List. The Bureau of Industry and Security (BIS) places entities
on the Entity List pursuant to part 744 (Control Policy: End-User and
End-Use Based) and part 746 (Embargoes and Other Special Controls) of
the EAR.
    The End-User Review Committee (ERC), composed of representatives of
the Departments of Commerce (Chair), State, Defense, Energy and, where
appropriate, the Treasury, makes all decisions regarding additions to,
removals from, or other modifications to the Entity List. The ERC makes
all decisions to add an entry to the Entity List by majority vote and
makes all decisions to remove or modify an entry by unanimous vote.

Additions to the Entity List

    The ERC determined to add AOOK Technology Ltd., under the
destination of China; CPUNTO Inc., under the destination of Canada;
Dexias Industrial Products and Trade Limited Company, under the
destination of Russia; Electronic Network Inc., under the destination
of Canada; Innovation and Technologies LLC, under the destination of
Russia; and Promtekhkomplekt JSC, under the destination of Russia, to
the Entity List. These additions are based on information that these
companies significantly contribute to Russia's military and/or defense
industrial base and are involved in activities contrary to U.S.
national security and foreign policy interests under Sec. Sec.  744.11
and 744.21 of the EAR. These entities will receive a footnote 3
designation because the ERC has determined that they are Russian or
Belarusian `military end users' in accordance with Sec.  744.21. A
footnote 3 designation subjects these entities to the Russia/Belarus-
Military End User Foreign Direct Product (FDP) rule, detailed under
Sec.  734.9(g). These entities are added with a license requirement for
all items subject to the EAR. License applications will be reviewed
under a policy of denial for all items subject to the EAR, other than
applications for food and medicine designated as EAR99, which will be
reviewed on a case-by-case basis.
    The ERC determined to add Beijing Ti-Tech Science and Technology
Development Co., under the destination of China; Beijing Yunze
Technology Co., Ltd., under the destination of China; China HEAD
Aerospace Technology Co., under the destinations of China, France, and
the Netherlands; and Spacety Co.,

Ltd., under the destinations of China and Luxembourg, to the Entity
List. These additions are based on information that these companies
significantly contribute to Russia's military and/or defense industrial
base and are involved in activities contrary to U.S. national security
and foreign policy interests under Sec. Sec.  744.11 and 744.21 of the
EAR. These entities will receive a footnote 3 designation because the
ERC has determined that they are Russian or Belarusian `military end
users' in accordance with Sec.  744.21. A footnote 3 designation
subjects these entities to the Russia/Belarus-Military End User Foreign
Direct Product (FDP) rule, detailed under Sec.  734.9(g). These
entities are added with a license requirement for all items subject to
the EAR. License applications for these entities will be reviewed under
a policy of denial for all items subject to the EAR, other than
applications for food and medicine designated as EAR99, which will be
reviewed on a case-by-case basis.
    For the reasons described above, this final rule adds the following
10 entities under 13 entries to the Entity List and includes, where
appropriate, aliases:

Canada

     CPUNTO Inc., and
     Electronic Network Inc.

China

     AOOK Technology Ltd.,
     Beijing Ti-Tech Science and Technology Development Co.,
     Beijing Yunze Technology Co., Ltd.,
     China HEAD Aerospace Technology Co., and
     Spacety Co. Ltd.

France

     China HEAD Aerospace Technology Co.

Luxembourg

     Spacety Co., Ltd.

Netherlands

     China HEAD Aerospace Technology Co.

Russia

     Dexias Industrial Products and Trade Limited Company,
     Innovation and Technologies LLC, and
     Promtekhkomplekt JSC.

Allied Governments Note

    BIS notes that this rule is meant to serve as a response to Russian
aggression against Ukraine. This rule does include entities in several
allied and partnered countries, but is not an action against the
countries in which the entities are located or registered or the
governments of those countries. This rule only serves as an action
against those entities listed, which have assisted the Russian
military, contrary to U.S. foreign and national security policy
interests.

Savings Clause

    For the changes being made in this final rule, shipments of items
removed from eligibility for a License Exception or export, reexport,
or transfer (in-country) without a license (NLR) as a result of this
regulatory action that were en route aboard a carrier to a port of
export, reexport, or transfer (in-country), on February 24th, pursuant
to actual orders for export, reexport, or transfer (in-country) to or
within a foreign destination, may proceed to that destination under the
previous eligibility for a License Exception or export, reexport, or
transfer (in-country) without a license (NLR).

Export Control Reform Act of 2018

    On August 13, 2018, the President signed into law the John S.
McCain National Defense Authorization Act for Fiscal Year 2019, which
included the Export Control Reform Act of 2018 (ECRA) (50 U.S.C. 4801-
4852). ECRA provides the legal basis for BIS's principal authorities
and serves as the authority under which BIS issues this rule.

Rulemaking Requirements

    1. This rule has been determined to be not significant for purposes
of Executive Order 12866.
    2. Notwithstanding any other provision of law, no person is
required to respond to or be subject to a penalty for failure to comply
with a collection of information, subject to the requirements of the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.) (PRA), unless
that collection of information displays a currently valid Office of
Management and Budget (OMB) Control Number. This regulation involves
collections previously approved by OMB under control number 0694-0088,
Simplified Network Application Processing System, which includes, among
other things, license applications and commodity classifications, and
carries a burden estimate of 29.4 minutes for a manual or electronic
submission for a total burden estimate of 33,133 hours. Total burden
hours associated with the PRA and OMB control number 0694-0088 are not
expected to increase as a result of this rule.
    3. This rule does not contain policies with federalism implications
as that term is defined in Executive Order 13132.
    4. Pursuant to section 1762 of the Export Control Reform Act of
2018, this action is exempt from the Administrative Procedure Act (5
U.S.C. 553) requirements for notice of proposed rulemaking, opportunity
for public participation, and delay in effective date.
    5. Because a notice of proposed rulemaking and an opportunity for
public comment are not required to be given for this rule by 5 U.S.C.
553, or by any other law, the analytical requirements of the Regulatory
Flexibility Act, 5 U.S.C. 601, et seq., are not applicable.
Accordingly, no regulatory flexibility analysis is required and none
has been prepared.

List of Subjects in 15 CFR Part 744

    Exports, Reporting and recordkeeping requirements, Terrorism.

    Accordingly, part 744 of the Export Administration Regulations (15
CFR parts 730-774) is amended as follows:

PART 744--CONTROL POLICY: END-USER AND END-USE BASED

0
1. The authority citation for 15 CFR part 744 continues to read as
follows:

    Authority: 50 U.S.C. 4801-4852; 50 U.S.C. 4601 et seq.; 50
U.S.C. 1701 et seq.; 22 U.S.C. 3201 et seq.; 42 U.S.C. 2139a; 22
U.S.C. 7201 et seq.; 22 U.S.C. 7210; E.O. 12058, 43 FR 20947, 3 CFR,
1978 Comp., p. 179; E.O. 12851, 58 FR 33181, 3 CFR, 1993 Comp., p.
608; E.O. 12938, 59 FR 59099, 3 CFR, 1994 Comp., p. 950; E.O. 13026,
61 FR 58767, 3 CFR, 1996 Comp., p. 228; E.O. 13099, 63 FR 45167, 3
CFR, 1998 Comp., p. 208; E.O. 13222, 66 FR 44025, 3 CFR, 2001 Comp.,
p. 783; E.O. 13224, 66 FR 49079, 3 CFR, 2001 Comp., p. 786; Notice
of September 19, 2022, 87 FR 57569 (September 21, 2022); Notice of
November 8, 2022, 87 FR 68015 (November 10, 2022).

0
2. Supplement No. 4 to part 744 is amended:
0
a. Under CANADA, by adding in alphabetical order, entries for ``CPUNTO
Inc.'' and ``Electronic Network Inc.'';
0
b. Under CHINA, PEOPLE'S REPUBLIC OF, by adding, in alphabetical order,
entries for ``AOOK Technology Ltd.''; ``Beijing Ti-Tech Science and
Technology Development Co.''; ``Beijing Yunze Technology Co., Ltd.'';
``China HEAD Aerospace Technology Co.''; and ``Spacety Co., Ltd.'';
0
c. Under FRANCE, by adding in alphabetical order, an entry for ``China
HEAD Aerospace Technology Co.'';
0
d. Under LUXEMBOURG, by adding in alphabetical order, an entry for
``Spacety Co., Ltd.'';

0
e. Under NETHERLANDS, by adding in alphabetical order, an entry for
``China HEAD Aerospace Technology Co.''; and
0
f. Under RUSSIA, by adding, in alphabetical order, entries for ``Dexias
Industrial Products and Trade Limited Company''; ``Innovation and
Technologies LLC''; and ``Promtekhkomplekt JSC''.

Supplement No. 4 to Part 744--Entity List

* * * * *

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
Country                  Entity                        License...........  License...........  Federal Register
                                                       requirement.......  review policy.....   citation
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
CANADA.................                                         * * * * * *
                         CPUNTO Inc., a.k.a., the      For all items       Policy of denial    88 FR [INSERT FR
                          following one alias:          subject to the      for all items       PAGE NUMBER AND
                         --CPUNTO.                      EAR. (See Sec.      subject to the      2/27/2023].
                         5929 Route Transcanadienne     Sec.                EAR apart from
                          Ste 130 St. Laurent, Quebec   734.9(g),\3\        food and medicine
                          H4T 1Z6 Canada.               744.21(b), and      designated as
                                                        746.8(a)(3) of      EAR99, which will
                                                        the EAR).           be reviewed on a
                                                                            case-by-case
                                                                            basis. See Sec.
                                                                            Sec.   746.8(b)
                                                                            and 744.21(e).
                                                                * * * * * *
                         Electronic Network Inc.,      For all items       Policy of denial    88 FR [INSERT FR
                          a.k.a., the following six     subject to the      for all items       PAGE NUMBER AND
                          aliases:                      EAR. (See Sec.      subject to the      2/27/2023].
                         --Electronic Network;          Sec.                EAR apart from
                         --Electronic Network           734.9(g),\3\        food and medicine
                          Holdings;                     744.21(b), and      designated as
                         --Electronic Network           746.8(a)(3) of      EAR99, which will
                          Holdings Inc.;                the EAR).           be reviewed on a
                         --Electronic Network                               case-by-case
                          Incorporated;                                     basis. See Sec.
                         --Electronic Network                               Sec.   746.8(b)
                          Products Inc.; and                                and 744.21(e).
                         --Electronic's Network &
                          Technology Corp.
                         145 Montee De Liesse Ste 10
                          St. Laurent, Quebec H4T 1T9
                          Canada.
                                                                * * * * * *
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
CHINA, PEOPLE'S                                                 * * * * * *
 REPUBLIC OF.
                         AOOK Technology Ltd.,         For all items       Policy of denial    88 FR [INSERT FR
                          a.k.a., the following two     subject to the      for all items       PAGE NUMBER AND
                          aliases:                      EAR. (See Sec.      subject to the      2/27/2023].
                         --AOOK; and                    Sec.                EAR apart from
                         --AOOK Electronics.            734.9(g),\3\        food and medicine
                         Rm 803 Chevalier Building 45-  744.21(b), and      designated as
                          51 Chatham Rd S Tsim Sha      746.8(a)(3) of      EAR99, which will
                          Tsui Hong Kong, China.        the EAR).           be reviewed on a
                                                                            case-by-case
                                                                            basis. See Sec.
                                                                            Sec.   746.8(b)
                                                                            and 744.21(e).
                                                                * * * * * *
                         Beijing Ti-Tech Science and   For all items       Policy of denial    88 FR [INSERT FR
                          Technology Development Co.,   subject to the      for all items       PAGE NUMBER AND
                          a.k.a., the following two     EAR. (See Sec.      subject to the      2/27/2023].
                          aliases:                      Sec.                EAR apart from
                         --Beijing Ti-Tech; and         734.9(g),\3\        food and medicine
                         --China Ti-Tech Development    744.21(b), and      designated as
                          Co. Ltd.                      746.8(a)(3) of      EAR99, which will
                         5F, Building 5 Science and     the EAR).           be reviewed on a
                          Technology Park, A-2 North                        case-by-case
                          Xisanhuan Road, Beijing                           basis. See Sec.
                          100081 China.                                     Sec.   746.8(b)
                                                                            and 744.21(e).
                                                                * * * * * *

                         Beijing Yunze Technology      For all items       Policy of denial    88 FR [INSERT FR
                          Co., Ltd., a.k.a., the        subject to the      for all items       PAGE NUMBER AND
                          following three aliases:      EAR. (See Sec.      subject to the      2/27/2023].
                         --Beijing Yunze;               Sec.                EAR apart from
                         --Beijing Yunze Technology     734.9(g),\3\        food and medicine
                          Company; and                  744.21(b), and      designated as
                         --Yunze Beijing.               746.8(a)(3) of      EAR99, which will
                         West of Floor 1, Building 7,   the EAR).           be reviewed on a
                          Jiajia Garden Courtyard 15,                       case-by-case
                          Fengtai Beijing 100000                            basis. See Sec.
                          China; and 201, Floor 2,                          Sec.   746.8(b)
                          36#, Yinhe Garden, Miyun                          and 744.21(e).
                          District Beijing 100000
                          China; and 402, Floor 4,
                          No. 85, Huilongguan W.
                          Street, Changping District
                          Beijing 102200 China.
                                                                * * * * * *
                         China HEAD Aerospace          For all items       Policy of denial    88 FR [INSERT FR
                          Technology Co., a.k.a., the   subject to the      for all items       PAGE NUMBER AND
                          following seven aliases:      EAR. (See Sec.      subject to the      2/27/2023].
                         --China HEAD;                  Sec.                EAR apart from
                         --China HEAD Technology Co;    734.9(g),\3\        food and medicine
                         --HEAD Aerospace;              744.21(b), and      designated as
                         --HEAD Aerospace Group;        746.8(a)(3) of      EAR99, which will
                         --HEAD Aerospace               the EAR).           be reviewed on a
                          Netherlands;                                      case-by-case
                         --HEAD France; and                                 basis. See Sec.
                         --HEAD Technology France.                          Sec.   746.8(b)
                                                                            and 744.21(e).
                         5F, Bldg 5, Science and
                          Technology Park, A-2 North
                          Xisanhuan Road, Haidian
                          District, Beijing 100081,
                          P.R. China; and Room 01,
                          floor 13, building 5, no.
                          A2 courtyard, west 3\rd\
                          ring r. Beijing, 10004-8,
                          China; and B-11a-02 Keshi
                          Plaza 28 Shangdi Xinxi Rd
                          Beijing 100058 China. (See
                          alternate address under
                          France and Netherlands).
                         Spacety Co., Ltd., a.k.a.,    For all items       Policy of denial    88 FR [INSERT FR
                          the following three           subject to the      for all items       PAGE NUMBER AND
                          aliases:                      EAR. (See Sec.      subject to the      2/27/2023].
                         --Changsha Tianyi Space        Sec.                EAR apart from
                          Science and Technology        734.9(g),\3\        food and medicine
                          Research Institute;           744.21(b), and      designated as
                         --Spacety; and                 746.8(a)(3) of      EAR99, which will
                         --Spacety Luxembourg S.A.      the EAR).           be reviewed on a
                         9 Dengzhuang South Rd                              case-by-case
                          Beijing, Beijing China; and                       basis. See Sec.
                          Room 445, 9\th\ Floor,                            Sec.   746.8(b)
                          Block B, No. 18                                   and 744.21(e).
                          Zhongguancun Street,
                          Haidian District, Beijing
                          China. (See alternate
                          address under Luxembourg).
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
FRANCE.................                                         * * * * * *
                         China HEAD Aerospace          For all items       Policy of denial    88 FR [INSERT FR
                          Technology Co., a.k.a., the   subject to the      for all items       PAGE NUMBER AND
                          following seven aliases:      EAR. (See Sec.      subject to the      2/27/2023].
                         --China HEAD;                  Sec.                EAR apart from
                         --China HEAD Technology Co;    734.9(g),\3\        food and medicine
                         --HEAD Aerospace;              744.21(b), and      designated as
                         --HEAD Aerospace Group;        746.8(a)(3) of      EAR99, which will
                         --HEAD Aerospace               the EAR).           be reviewed on a
                          Netherlands;                                      case-by-case
                         --HEAD France; and                                 basis. See Sec.
                         --HEAD Technology France.                          Sec.   746.8(b)
                                                                            and 744.21(e).
                         71 Boulevard national, 92250
                          La Garenne-Colombes Paris,
                          France. (See alternate
                          address under China and
                          Netherlands).
                                                                * * * * * *
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
LUXEMBOURG.............                                         * * * * * *

                         Spacety Co., Ltd., a.k.a.,    For all items       Policy of denial    88 FR [INSERT FR
                          the following three           subject to the      for all items       PAGE NUMBER AND
                          aliases:                      EAR. (See Sec.      subject to the      2/27/2023].
                         --Changsha Tianyi Space        Sec.                EAR apart from
                          Science and Technology        734.9(g),\3\        food and medicine
                          Research Institute;           744.21(b), and      designated as
                         --Spacety; and                 746.8(a)(3) of      EAR99, which will
                         --Spacety Luxembourg S.A.      the EAR).           be reviewed on a
                         9, Avenue des Hauts-                               case-by-case
                          Fourneaux, L-4362 Esch-Sur-                       basis. See Sec.
                          Alzette, Luxembourg. (See                         Sec.   746.8(b)
                          alternate address under                           and 744.21(e).
                          China).
                                                                * * * * * *
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
NETHERLANDS............                                         * * * * * *
                         China HEAD Aerospace          For all items       Policy of denial    88 FR [INSERT FR
                          Technology Co., a.k.a., the   subject to the      for all items       PAGE NUMBER AND
                          following seven aliases:      EAR. (See Sec.      subject to the      2/27/2023].
                         --China HEAD;                  Sec.                EAR apart from
                         --China HEAD Technology Co;    734.9(g),\3\        food and medicine
                         --HEAD Aerospace;              744.21(b), and      designated as
                         --HEAD Aerospace Group;        746.8(a)(3) of      EAR99, which will
                         --HEAD Aerospace               the EAR).           be reviewed on a
                          Netherlands;                                      case-by-case
                         --HEAD France; and                                 basis. See Sec.
                         --HEAD Technology France.                          Sec.   746.8(b)
                         Kapteynstraat 1 2201 BB                            and 744.21(e).
                          Noordwijk ZH, Netherlands.
                          (See alternate address
                          under China and France).
                                                                * * * * * *
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
RUSSIA.................
                         Dexias Industrial Products    For all items       Policy of denial    88 FR [INSERT FR
                          and Trade Limited Company,    subject to the      for all items       PAGE NUMBER AND
                          a.k.a., the following five    EAR. (See Sec.      subject to the      2/27/2023].
                          aliases:                      Sec.                EAR apart from
                         --Dexias;                      734.9(g),\3\        food and medicine
                         --Dexias Endil strivel;        744.21(b), and      designated as
                         --Dexias IPTLC;                746.8(a)(3) of      EAR99, which will
                         --Mainbox LLC; and             the EAR).           be reviewed on a
                         --Orunler ve Ticaret Limited                       case-by-case
                          Sirketi.                                          basis. See Sec.
                         Apartment 261, Building 3,                         Sec.   746.8(b)
                          Ryabinovaya Street, Moscow,                       and 744.21(e).
                          Russia.
                                                                * * * * * *
                         Innovation and Technologies   For all items       Policy of denial    88 FR [INSERT FR
                          LLC, a.k.a., the following    subject to the      for all items       PAGE NUMBER AND
                          two aliases:                  EAR. (See Sec.      subject to the      2/27/2023].
                         --Intekh; and                  Sec.                EAR apart from
                         --INTEKH OOO.                  734.9(g),\3\        food and medicine
                         D. 83 K. 3 OFIS 516, Ul.       744.21(b), and      designated as
                          Savushkina, St. Petersburg    746.8(a)(3) of      EAR99, which will
                          197374 Russia; and Mira       the EAR).           be reviewed on a
                          prospect, 2-7 601901                              case-by-case
                          Kovrov, Russia.                                   basis. See Sec.
                                                                            Sec.   746.8(b)
                                                                            and 744.21(e).
                                                                * * * * * *
                         Promtekhkomplekt JSC,         For all items       Policy of denial    88 FR [INSERT FR
                          a.k.a., the following four    subject to the      for all items       PAGE NUMBER AND
                          aliases:                      EAR. (See Sec.      subject to the      2/27/2023].
                         --AO TipoMTeXKOMirneKT;        Sec.                EAR apart from
                         --Promtech Komplekt;           734.9(g),\3\        food and medicine
                         --Promtekhkomplekt; and        746.8(a)(3), and    designated as
                         --Promtekhkomplekt Joint       744.21(b) of the    EAR99, which will
                          Stock Company.                EAR).               be reviewed on a
                         MKAD Greenwood Business Park                       case-by-case
                          building 9 floor 3, pos.                          basis. See Sec.
                          Putilko o, 69 km., Moscow                         Sec.   746.8(b)
                          region, 143441, Russia; and                       and 744.21(e).
                          6/1 Griboyedov Street,
                          OF.23, Tyumen, Tyumen
                          Oblast, Russia.

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------

* * * * *

Thea D. Rozman Kendler,
Assistant Secretary for Export Administration.
[FR Doc. 2023-03929 Filed 2-24-23; 8:45 am]
BILLING CODE 3510-JT-P


[Federal Register: October 3, 2005 (Volume 70, Number 190)]
[Notices]
[Page 57594-57595]
[DOCID:fr03oc05-98]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Application Accepted for Filing and Soliciting
Comments, Protests, and Motions To Intervene

September 23, 2005.
    Take notice that the following hydroelectric application has been
filed with the Commission and is available for public inspection:
    a. Type of Application: Preliminary Permit.
    b. Project No.: 12581-000.
    c. Date filed: March 31, 2005.
    d. Applicant: Cambria Somerset Authority.
    e. Name and Location of Project: The proposed Que Pumped Storage
Project would be located in Quemahoning Township, Somerset County,
Pennsylvania.
    f. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)-825(r).
    g. Applicant contact: Mr. Paul C. Rizzo, Paul C. Rizzo Associates,
Inc., 647 Main Street, Suite 200, Johnstown, PA 15901,<PHONE_NUMBER>.
    h. FERC Contact: Tom Papsidero,<PHONE_NUMBER>.
    i. Deadline for filing comments, protests, and motions to
intervene: 60 days from the issuance date of this notice.
    All documents (original and eight copies) should be filed with
Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888
First Street, NE., Washington, DC 20426. Comments, protests and
interventions may be filed electronically via the Internet in lieu of
paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the
Commission's Web site under the ``e-Filing'' link. The Commission
strongly encourages electronic filings. Please include the project
number (P-12581-000) on any comments or motions filed.
    The Commission's Rules of Practice and Procedure require all
intervenors filing documents with the Commission to serve a copy of
that document on each person in the official service list for the
project. Further, if an intervenor files comments or documents with the
Commission relating to the merits of an issue that may affect the
responsibilities of a particular resource agency, they must also serve
a copy of the document on that resource agency.
    j. Description of Existing Facilities and Proposed Project: The
proposed project would consist of the following facilities: (1) A new
upper reservoir with a maximum storage capacity of 1,549.8 acre-feet
and a surface area of 30 acres at maximum normal water surface
elevation of 2088 feet above mean sea level (msl); (2) a new upper
concrete intake structure with a steel penstock; (3) a new lower
concrete and steel intake structure; (4) a new powerhouse with two 50-
megawatt pump/turbines; (5) an existing lower reservoir with a maximum
storage capacity of 36,212.9 acre-feet and an area of 928 acres at
maximum water surface elevation of 1625 feet msl; (6) a new
transmission line between the powerhouse and switchyard and an existing
transmission line approximately 7300-feet-long to the southeast; and
(7) appurtenant facilities. The proposed project would have an annual
generation of 156 GWh.
    k. Location of Applications: A copy of the application is available
for inspection and reproduction at the Commission in the Public
Reference Room or may be viewed on the Commission's Web site at http://www.ferc.gov
 using the ``eLibrary'' link. Enter the docket number

excluding the last three digits in the docket number field to access
the document. For assistance, call toll-free 1-866-208-3676 or e-mail
<EMAIL_ADDRESS>For TTY, call<PHONE_NUMBER>. A copy is

also available for inspection and reproduction at the address in item g
above.
    l. Individuals desiring to be included on the Commission's mailing
list should so indicate by writing to the Secretary of the Commission.
    m. Competing Preliminary Permit--Anyone desiring to file a
competing application for preliminary permit for a proposed project
must submit the competing application itself, or a notice of intent to
file such an application, to the Commission on or before the specified
comment date for the particular application (see 18 CFR 4.36).
Submission of a timely notice of intent allows an interested person to
file the competing preliminary permit application no later than 30 days
after the specified comment date for the particular application. A
competing preliminary permit application must conform with 18 CFR
4.30(b) and 4.36.
    n. Competing Development Application--Any qualified development
applicant desiring to file a competing development application must
submit to the Commission, on or before a specified comment date for the
particular application, either a competing development application or a
notice of intent to file such an application. Submission of a timely
notice of intent to file a development application allows an interested
person to file the competing application no later than 120 days after
the specified comment date for the particular application. A competing
license application must conform with 18 CFR 4.30(b) and 4.36.
    o. Notice of Intent--A notice of intent must specify the exact
name, business address, and telephone number of the prospective
applicant, and must include an unequivocal statement of intent to
submit, if such an application may be filed, either a preliminary
permit application or a development application (specify which type of
application). A notice of intent must be served on the applicant(s)
named in this public notice.
    p. Proposed Scope of Studies Under Permit--A preliminary permit, if
issued, does not authorize construction. The term of the proposed
preliminary permit would be 36 months. The work proposed under the
preliminary permit would include economic analysis, preparation of
preliminary engineering plans, and a study of environmental impacts.
Based on the results of these studies, the Applicant would decide
whether to proceed with the preparation of a development application to
construct and operate the project.
    q. Comments, Protests, or Motions To Intervene--Anyone may submit
comments, a protest, or a motion to intervene in accordance with the
requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211,
.214. In determining the appropriate action to take, the Commission
will consider all protests or other comments filed, but only those who
file a motion to intervene in accordance with the Commission's Rules
may become a party to the proceeding. Any comments, protests, or
motions to intervene must be received on or before the specified
comment date for the particular application.
    Comments, protests and interventions may be filed electronically
via the Internet in lieu of paper; See 18 CFR 385.2001 (a)(1)(iii) and
the instructions on the Commission's Web site under ``e-

filing'' link. The Commission strongly encourages electronic filing.
    r. Filing and Service of Responsive Documents--Any filings must
bear in all capital letters the title ``COMMENTS'', ``NOTICE OF INTENT
TO FILE COMPETING APPLICATION'', ``COMPETING APPLICATION'',
``PROTEST'', or ``MOTION TO INTERVENE'', as applicable, and the Project
Number of the particular application to which the filing refers. Any of
the above-named documents must be filed by providing the original and
the number of copies provided by the Commission's regulations to: The
Secretary, Federal Energy Regulatory Commission, 888 First Street, NE.,
Washington, DC 20426. An additional copy must be sent to Director,
Division of Hydropower Administration and Compliance, Federal Energy
Regulatory Commission, at the above-mentioned address. A copy of any
notice of intent, competing application or motion to intervene must
also be served upon each representative of the Applicant specified in
the particular application.
    s. Agency Comments--Federal, State, and local agencies are invited
to file comments on the described application. A copy of the
application may be obtained by agencies directly from the Applicant. If
an agency does not file comments within the time specified for filing
comments, it will be presumed to have no comments. One copy of an
agency's comments must also be sent to the Applicant's representatives.

Magalie R. Salas,
Secretary.
 [FR Doc. E5-5376 Filed 9-30-05; 8:45 am]

BILLING CODE 6717-01-P